三氟甲基喹唑啉化合物抑制耐药性胶质母细胞瘤的增殖.

The current treatment of glioma is facing drug resistance, which limits the efficacy of traditional chemotherapy drugs. This study aims to explore the potential mechanisms of the trifluoromethylquinazoline compound (KZL204) against glioma. Through the Cell Counting Kit-8 (CCK- 8) assay, we found that KZL204 significantly inhibits the growth of drug-resistant cancer cells, with a 48-hour half-maximal inhibitory concentration (IC50) of 3.63±0.38 µmol/L, which is significantly better than the positive control drug temozolomide (TMZ) (IC50 value of 81.67±5. 49 µmol/L). Additionally, flow cytometry analysis showed that KZL204 treatment significantly increased the apoptosis rate of drug-resistant tumor cells and arrested the cell cycle at the G2/M phase. At the same time, the Transwell assay confirmed the inhibitory effect of KZL204 on the migration and invasion of drug-resistant cancer cells. Transcriptome analysis revealed 2 435 differentially expressed genes in drug-resistant cancer cells treated with KZL204, of which 1 320 were upregulated, and 1 115 were downregulated. KEGG and GO enrichment analysis showed that these differential genes were significantly enriched in apoptosis-related signaling pathways. Further bioinformatics prediction and Venn diagram analysis identified 35 potential core targets, with the PI3K-AKT signaling pathway being the most significant among the differentially expressed genes. Quantitative real-time PCR (RT-qPCR) experiments confirmed the downregulating effects of KZL204 on genes such as CREB3L1, CSF1, CXCL5, BCL3, and the upregulating effects on genes like FOS, LTA, PTGS2, MAP2K3. Immunoblotting experiments at the protein level also confirmed the impact of KZL204 on the expression of apoptotic proteins, including the upregulation of Bax, cleaved Caspase-3 protein, and the downregulation ofAKT, Bcl-2, Caspase-3, and Caspase-8 protein expression. In summary, KZL204 significantly inhibits the growth and metastasis of drug-resistant glioblastoma and induces apoptosis and cell cycle arrest by regulating the PI3K-AKT and apoptosis-related signaling pathways, demonstrating its potential as a candidate drug against drug-resistant glioma. [ABSTRACT FROM AUTHOR]